Valganciclovir: Recent progress

American Journal of Transplantation

Volumn 10, Issue 6, 2010, Pages 1359-1364

  Pescovitz, M D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Children; Cytomegalovirus; Ganciclovir; Pharmacokinetics; Review; Transplant; Treatment; Valganciclovir

Indexed keywords

GANCICLOVIR; PLACEBO; VALGANCICLOVIR;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEART TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETINITIS; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; VIREMIA; ANALOGS AND DERIVATIVES; CHILD; CLINICAL TRIAL (TOPIC); HIV SEROPOSITIVITY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CHILD; CLINICAL TRIALS AS TOPIC; GANCICLOVIR; HIV SEROPOSITIVITY; HUMANS;

EID: 77952919229     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03112.x     Document Type: Short Survey

References (30)

1. Pescovitz MD. Valganciclovir. Transplant Rev 2006 20 : 82 87.
2. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4 : 611 620.
3. Balfour J, Henry H, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989 320 : 1381 1388.
4. Brennan DC, Garlock KA, Singer GG et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997 64 : 1843 1846.
5. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999 340 : 1462 1470.
6. Humar A, Paya C, Pescovitz MD et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+R- solid organ transplant recipients. Am J Transplant 2004 4 : 644 649.
7. Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006 81 : 1106 1111.
8. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004 4 : 1635 1642.
9. Helantera I, Lautenschlager I, Koskinen P. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009 24 : 316 320.
10. Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant In press.
11. Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009 9 : 1214 1222.
12. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 44 : 2811 2815.
13. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004 189 : 1615 1618.
14. Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005 44 : 495 507.
15. Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005 79 : 1477 1483.
16. Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: Pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009 48 : 399 418.
17. Chamberlain CE, Penzak SR, Alfaro RM et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008 8 : 1297 1302.
18. Dupuis R, Harris M, Gillis K et al. Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients. Transplant Proc 2007 39 : 3266 3270.
19. Akalin E, Sehgal V, Ames S et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003 3 : 731 735.
20. Clark BS, Chang IF, Karpen SJ et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004 77 : 1480.
21. Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007 11 : 301 305.
22. Zhao W, Baudouin V, Zhang D, Deschenes G, Guellec CL, Jacqz-Aigrain E. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin Pharmacokinet 2009 48 : 321 328.
23. Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc 2007 39 : 3111 3116.
24. Pescovitz MD, Ettenger RB, Strife CF et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis (in press).
25. Vaudry W, Ettenger R, Jara P et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009 9 : 636 643.
26. Asberg A, Humar A, Rollag H et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007 7 : 2106 2113.
27. Asberg A, Humar A, Jardine AG et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009 9 : 1205 1213.
28. Caldes A, Gil-Vernet S, Armendariz Y et al. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: Efficacy, safety, and pharmacokinetics. Transpl Infect Dis 2009 (in press).
29. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS One 2009 4 : e5512.
30. Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 2009 15 : 963 967.